annual accounts payable:
$88.42M+$32.90M(+59.25%)Summary
- As of today (June 22, 2025), ALNY annual accounts payable is $88.42 million, with the most recent change of +$32.90 million (+59.25%) on December 31, 2024.
- During the last 3 years, ALNY annual accounts payable has risen by +$14.99 million (+20.41%).
- ALNY annual accounts payable is now -9.87% below its all-time high of $98.09 million, reached on December 31, 2022.
Performance
ALNY Accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly accounts payable:
$97.40M+$8.98M(+10.16%)Summary
- As of today (June 22, 2025), ALNY quarterly accounts payable is $97.40 million, with the most recent change of +$8.98 million (+10.16%) on March 31, 2025.
- Over the past year, ALNY quarterly accounts payable has increased by +$19.25 million (+24.63%).
- ALNY quarterly accounts payable is now -0.71% below its all-time high of $98.09 million, reached on December 31, 2022.
Performance
ALNY quarterly accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
ALNY Accounts payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +59.3% | +24.6% |
| 3 y3 years | +20.4% | +77.4% |
| 5 y5 years | +77.2% | +140.6% |
ALNY Accounts payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -9.9% | +59.3% | -0.7% | +140.1% |
| 5 y | 5-year | -9.9% | +77.2% | -0.7% | +272.8% |
| alltime | all time | -9.9% | >+9999.0% | -0.7% | >+9999.0% |
ALNY Accounts payable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $97.40M(+10.2%) |
| Dec 2024 | $88.42M(+59.3%) | $88.42M(+24.9%) |
| Sep 2024 | - | $70.81M(-4.3%) |
| Jun 2024 | - | $73.98M(-5.3%) |
| Mar 2024 | - | $78.15M(+40.8%) |
| Dec 2023 | $55.52M(-43.4%) | $55.52M(-24.8%) |
| Sep 2023 | - | $73.84M(+23.6%) |
| Jun 2023 | - | $59.75M(-4.0%) |
| Mar 2023 | - | $62.24M(-36.6%) |
| Dec 2022 | $98.09M(+33.6%) | $98.09M(+141.8%) |
| Sep 2022 | - | $40.57M(-22.6%) |
| Jun 2022 | - | $52.42M(-4.5%) |
| Mar 2022 | - | $54.92M(-25.2%) |
| Dec 2021 | $73.43M(+41.3%) | $73.43M(+83.3%) |
| Sep 2021 | - | $40.05M(-24.6%) |
| Jun 2021 | - | $53.08M(+17.0%) |
| Mar 2021 | - | $45.38M(-12.7%) |
| Dec 2020 | $51.97M(+4.2%) | $51.97M(+86.4%) |
| Sep 2020 | - | $27.87M(+6.7%) |
| Jun 2020 | - | $26.13M(-35.5%) |
| Mar 2020 | - | $40.48M(-18.8%) |
| Dec 2019 | $49.88M(-16.5%) | $49.88M(+26.6%) |
| Sep 2019 | - | $39.39M(-44.7%) |
| Jun 2019 | - | $71.22M(+214.1%) |
| Mar 2019 | - | $22.67M(-62.0%) |
| Dec 2018 | $59.71M(+110.6%) | $59.71M(+174.2%) |
| Sep 2018 | - | $21.77M(+81.6%) |
| Jun 2018 | - | $11.99M(-9.2%) |
| Mar 2018 | - | $13.21M(-53.4%) |
| Dec 2017 | $28.36M(-47.9%) | $28.36M(+206.9%) |
| Sep 2017 | - | $9.24M(-60.1%) |
| Jun 2017 | - | $23.17M(-8.7%) |
| Mar 2017 | - | $25.37M(-53.4%) |
| Dec 2016 | $54.47M(+224.4%) | $54.47M(+135.4%) |
| Sep 2016 | - | $23.14M(+80.4%) |
| Jun 2016 | - | $12.82M(-26.5%) |
| Mar 2016 | - | $17.44M(+3.9%) |
| Dec 2015 | $16.79M(+11.1%) | $16.79M(+17.6%) |
| Sep 2015 | - | $14.27M(-9.2%) |
| Jun 2015 | - | $15.71M(+1.5%) |
| Mar 2015 | - | $15.49M(+2.5%) |
| Dec 2014 | $15.11M | $15.11M(+190.5%) |
| Sep 2014 | - | $5.20M(-15.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2014 | - | $6.17M(+22.5%) |
| Mar 2014 | - | $5.04M(-14.6%) |
| Dec 2013 | $5.90M(+33.4%) | $5.90M(+116.1%) |
| Sep 2013 | - | $2.73M(-39.8%) |
| Jun 2013 | - | $4.53M(+46.0%) |
| Mar 2013 | - | $3.10M(-29.8%) |
| Dec 2012 | $4.42M(-23.8%) | $4.42M(-13.2%) |
| Sep 2012 | - | $5.09M(-7.7%) |
| Jun 2012 | - | $5.52M(+27.2%) |
| Mar 2012 | - | $4.34M(-25.2%) |
| Dec 2011 | $5.80M(-37.7%) | $5.80M(+5.7%) |
| Sep 2011 | - | $5.49M(-31.0%) |
| Jun 2011 | - | $7.95M(+37.1%) |
| Mar 2011 | - | $5.80M(-37.7%) |
| Dec 2010 | $9.31M(-25.4%) | $9.31M(+41.9%) |
| Sep 2010 | - | $6.56M(-36.9%) |
| Jun 2010 | - | $10.40M(+48.8%) |
| Mar 2010 | - | $6.99M(-44.0%) |
| Dec 2009 | $12.49M(+382.6%) | $12.49M(+48.2%) |
| Sep 2009 | - | $8.43M(+30.4%) |
| Jun 2009 | - | $6.46M(-26.0%) |
| Mar 2009 | - | $8.73M(+237.3%) |
| Dec 2008 | $2.59M(-32.4%) | $2.59M(-22.6%) |
| Sep 2008 | - | $3.34M(-46.4%) |
| Jun 2008 | - | $6.24M(-31.3%) |
| Mar 2008 | - | $9.08M(+137.4%) |
| Dec 2007 | $3.83M(-6.3%) | $3.83M(-45.8%) |
| Sep 2007 | - | $7.06M(+24.5%) |
| Jun 2007 | - | $5.67M(+88.5%) |
| Mar 2007 | - | $3.01M(-26.4%) |
| Dec 2006 | $4.08M(+106.8%) | $4.08M(+66.3%) |
| Sep 2006 | - | $2.46M(-33.6%) |
| Jun 2006 | - | $3.70M(-5.9%) |
| Mar 2006 | - | $3.93M(+98.9%) |
| Dec 2005 | $1.98M(+117.0%) | $1.98M(-0.5%) |
| Sep 2005 | - | $1.99M(+23.1%) |
| Jun 2005 | - | $1.61M(-2.5%) |
| Mar 2005 | - | $1.65M(+81.6%) |
| Dec 2004 | $910.00K(-39.7%) | $910.00K(-37.2%) |
| Sep 2004 | - | $1.45M(-19.9%) |
| Jun 2004 | - | $1.81M(-50.2%) |
| Mar 2004 | - | $3.64M(+140.8%) |
| Dec 2003 | $1.51M(+124.0%) | $1.51M |
| Dec 2002 | $674.00K | - |
FAQ
- What is Alnylam Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual accounts payable year-on-year change?
- What is Alnylam Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly accounts payable year-on-year change?
What is Alnylam Pharmaceuticals annual accounts payable?
The current annual accounts payable of ALNY is $88.42M
What is the all time high annual accounts payable for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual accounts payable is $98.09M
What is Alnylam Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, ALNY annual accounts payable has changed by +$32.90M (+59.25%)
What is Alnylam Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of ALNY is $97.40M
What is the all time high quarterly accounts payable for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly accounts payable is $98.09M
What is Alnylam Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, ALNY quarterly accounts payable has changed by +$19.25M (+24.63%)